Becky Pferdehirt | Partner
Andreessen Horowitz

Becky Pferdehirt, Partner, Andreessen Horowitz

Becky Pferdehirt is an investing partner on the a16z Bio + Health team. Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation. Becky completed her postdoctoral education at Genentech, studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT.


Day 3 - November 30 @ 09:40

Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

  • Could new platform technologies enable us to develop countermeasures rapidly enough to stop emerging viral threats before pandemics ensue?
  • Are broad-spectrum (pan-variant) prophylactics a possible way forward?
  • When will we see the first clinically approved mRNA or DNA-encoded therapeutics, from gene-editing to immunotherapy?
  • Could advances in AI and synthetic biology enable personalized medicines (e.g. for cancers) to be developed at a population scale?
  • Would regulators agree to accelerate approval of platform-based medicines based on the safety and efficacy of different candidates from the same platform?
  • Can Government, biopharma, and venture capital co-fund platform technologies, especially for technologies of dual commercial and national security interest?
last published: 02/Jan/24 12:15 GMT

back to speakers